Literature DB >> 9528894

Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD).

R Giacomelli1, A Passacantando, I Parzanese, P Vernia, N Klidara, F Cucinelli, R Lattanzio, E Santori, P Cipriani, R Caprilli, G Tonietti.   

Abstract

Imbalance in Th1 and Th2 subsets and their derived cytokines seems to be involved in the immune abnormalities underlying UC and CD. CD30 is a member of the tumour necrosis factor/nerve growth receptor superfamily expressed on T cells producing Th2 cytokines and released as a soluble form. In this study high levels of soluble CD30 were found in sera of UC patients independently of disease activity. Furthermore, increased titres of soluble CD30 molecule were shown, in the same patients, by mitogen-stimulated cultures of peripheral blood mononuclear cells. Our data seem to indicate that an activation of Th2 immune response is involved in the pathogenesis of UC, but not of CD. Furthermore, this finding indicates that serum soluble CD30 measurement may be helpful for differentiating these two forms of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9528894      PMCID: PMC1904890          DOI: 10.1046/j.1365-2249.1998.00532.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

Review 2.  The expanding universe of T-cell subsets: Th1, Th2 and more.

Authors:  T R Mosmann; S Sad
Journal:  Immunol Today       Date:  1996-03

3.  CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors.

Authors:  B Agrawal; M Reddish; B M Longenecker
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

4.  CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity.

Authors:  M Alzona; H M Jäck; R I Fisher; T M Ellis
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

5.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

6.  Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity.

Authors:  F Caligaris-Cappio; M T Bertero; M Converso; A Stacchini; F Vinante; S Romagnani; G Pizzolo
Journal:  Clin Exp Rheumatol       Date:  1995 May-Jun       Impact factor: 4.473

7.  Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines.

Authors:  G Del Prete; M De Carli; F Almerigogna; C K Daniel; M M D'Elios; G Zancuoghi; F Vinante; G Pizzolo; S Romagnani
Journal:  FASEB J       Date:  1995-01       Impact factor: 5.191

8.  High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints.

Authors:  R Gerli; C Muscat; O Bistoni; B Falini; C Tomassini; E Agea; R Tognellini; P Biagini; A Bertotto
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

9.  CD30 expression does not discriminate between human Th1- and Th2-type T cells.

Authors:  D Hamann; C M Hilkens; J L Grogan; S M Lens; M L Kapsenberg; M Yazdanbakhsh; R A van Lier
Journal:  J Immunol       Date:  1996-02-15       Impact factor: 5.422

10.  Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).

Authors:  M Niessner; B A Volk
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

View more
  15 in total

1.  The pathogenesis of Barrett's esophagus: a process in continuum or discontinuum.

Authors:  R C Fitzgerald; M J Farthing
Journal:  Curr Gastroenterol Rep       Date:  2000-12

2.  The bacterial pathogenesis and treatment of pouchitis.

Authors:  S D McLaughlin; S K Clark; P P Tekkis; R J Nicholls; P J Ciclitira
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

3.  Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants.

Authors:  R C Fitzgerald; B A Onwuegbusi; M Bajaj-Elliott; I T Saeed; W R Burnham; M J G Farthing
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

4.  Concise Commentary: Calling in Your Marker-Rectal CD30-Positive Cells Differentiate Ulcerative Colitis from Crohn's Disease.

Authors:  Mathieu Uzzan
Journal:  Dig Dis Sci       Date:  2018-07       Impact factor: 3.199

Review 5.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

6.  CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease.

Authors:  Shinichi Somada; Hiromi Muta; Kazuhiko Nakamura; Xun Sun; Kuniomi Honda; Eikichi Ihara; Hirotada Akiho; Ryoichi Takayanagi; Yasunobu Yoshikai; Eckhard R Podack; Kenzaburo Tani
Journal:  Dig Dis Sci       Date:  2012-03-27       Impact factor: 3.199

7.  Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease.

Authors:  T Spieker; H Herbst
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

8.  Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis.

Authors:  Ondrej Fabian; Ondrej Hradsky; Tereza Drskova; Filip Mikus; Josef Zamecnik; Jiri Bronsky
Journal:  Dig Dis Sci       Date:  2018-03-14       Impact factor: 3.199

Review 9.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications.

Authors:  Nima Rezaei; Mostafa Haji-Molla-Hoseini; Asghar Aghamohammadi; Ali Akbar Pourfathollah; Mina Moghtadaie; Zahra Pourpak
Journal:  J Clin Immunol       Date:  2007-10-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.